BriaCell Therapeutics Corp. announces US $ 27.2 million
BERKELEY, Calif. And VANCOUVER, British Columbia, June 3, 2021 (GLOBE NEWSWIRE) – BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX-V: BCT) (the “Company” or “BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that ” it has entered into definitive securities purchase agreements with accredited investors, which will result in gross proceeds to BriaCell of approximately US $ 27.2 million, before the deduction of offering offering fees. BriaCell will issue 5,170,343 units, each unit consisting of one common share and one common share warrant (or units made up of one common share purchase warrant). pre-financed (“pre-financed warrant”)) and a subscription warrant, in lieu of it). Each unit is sold to the public at a price of US $ 5.26 (including the exercise price of the pre-funded warrant, in the case of units containing pre-funded warrants). The warrants have a term of five and a half years and an exercise price of US $ 6.19 per share. This private placement is expected to close on June 7, 2021, subject to customary closing conditions.
The securities offered and sold by BriaCell under the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or state securities laws and cannot be offered or sold in the United States without registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from these registration requirements. BriaCell has agreed to file a registration statement with the SEC covering the resale of the common shares and the shares underlying the warrants to be issued under the private placement. Any resale of BriaCell shares under this resale registration statement will be made only by means of a prospectus.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. before registration or qualification. under the securities laws of any such state or jurisdiction. The securities will not be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States except under an exemption from the registration requirements of the Securities Act and applicable state laws.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company that develops targeted and effective approaches for cancer management. More information is available at https://briacell.com.
This press release contains “forward-looking statements” which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate”, “believe”, “contemplate”, “might”, “estimate”, “expect”, “have l ‘intention to’, ‘search’, ‘. “” May “,” could “,” ‘or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions which are difficult to predict. In addition, certain forward-looking statements are based on assumptions about future events which may not prove to be correct. These and other risks and uncertainties are described in more detail under the heading “Risks and uncertainties” in the most recent management report of the Company, under “Risks and uncertainties” and in other documents filed by the Company. with the Canadian Securities Regulatory Authority and the United States Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. The forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. assumes no obligation to update this information, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Company details :
William V. Williams, MD
President and CEO
Director of Public Relations
Investor Relations Contact: